hormonal therapy | Ricerc@Sapienza

"Pelvic ultrasound evaluation in transgender male during testosterone therapy" G. Senofonte, E. Marcoccia, C. Boccherini, M. Marasco, A. Perlorca, G. Nigro, A. Giancotti, M. Mosconi, F. Lombardo

Introduction: Gender dysphoria (GD) is characterised by significant distress and/or poor
social functioning due to a non-congruence between an individual’s assigned gender and the
perceived gender identity. In Female to Male subjects, androgen therapy aims to induce
physical changes (such as hair growth, tone voice decrease, fat mass redistribution, breast
volume reduction, etc) and cessation of menses. The latest guidelines (Hembree, 2017)
suggest a higher risk of malignancies (uterus and ovaries) and of endometrial hyperplasia than

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience

Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6-35.4) and clinical benefit was 52.7% (95% CI, 48-57.5).